📰 Induction Study News
Induction Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Induction Study. Real-time updates on events, politics, business and more.
December 1, 2023
November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.
November 22, 2023
After a negative review by an Independent Data Monitoring Committee, InDex Pharmaceuticals has decided to discontinue the late-stage CONCLUDE program evaluating its cobitolimod in ulcerative colitis.
November 22, 2023
This phase 3 program was advised to discontinue given that cobitolimod was shown to be less likely to meet its primary endpoint.
November 21, 2023
/PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals") today announces that an independent DMC has completed the planned dose...
November 21, 2023
STOCKHOLM, Nov. 21, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals")...
November 21, 2023
/PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals") today announces that an independent DMC has completed the planned dose...
October 11, 2023
STOCKHOLM, Oct. 11, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that 30% of...
October 5, 2023
/PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) will attend the United European Gastroenterology Week (UEGW), one of the worlds leading...
May 31, 2023
STOCKHOLM, May 31, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex") today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc. ("Viatris
May 31, 2023
May 31, 2023 - InDex Pharmaceuticals Holding AB today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc. to register and commercialize cobitolimod in Japan... | June 7, 2023